AX-2026-042276 · SLU-PP-332 · Homopeptide lot HOMO-2602-Y2822

Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.58	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.42	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — hydrolysed ester (+18 Da)	0.15	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	410.1300	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	410.1306	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+1.5	ppm	± 10	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.95	%	≤ 10.0	PASS
Counter-ion	no ionisable counter-ion expected	N/A	—	not applicable	NOT TESTED
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.73	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partially collapsed	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear with a single visible fibre	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	7.71	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	15.18	min	15.28 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.95	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	74,915	—	≥ 20,000	PASS
Resolution to nearest impurity	vs des-methyl analogue (−14 Da)	1.58	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 74,915, and skew follows the reported asymmetry factor of 0.95. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.15 % impurity against a 99.58 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	SLU-PP-332 — main peak	15.18	4,839,897	99.58	—
2	hydrolysed ester (+18 Da)	13.94	7,290	0.15	+18.011
3	residual DMSO (process solvent)	5.08	6,804	0.14	0.000
4	sulfoxide (+16 Da)	14.46	3,888	0.08	+15.995
5	des-methyl analogue (−14 Da)	14.82	2,430	0.05	-14.016
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 410.1300 Da, computed from C22H22N2O4S. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 410.1306 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
1+	411.1373	411.1379	0.0006	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.58	divergence +0.39 pp vs batch median
Total impurities (% area)	0.10	0.42
Largest single impurity (% area)	0.06	0.15
Water (%)	3.7	4.95
Counter-ion (%)	4.4	N/A
Peptide content (%w/w)	91.3	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 12 d) → assay. Submitter did not handle the vial.
Assay date: 21 Aug 2026
Submitted to the index: 14 Sep 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot HOMO-2602-Y2822 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042273	HOMO-2602-Y2822	PeptideMeter	2026-Q3	99.81	4.60	88.9	Supplier-supplied	2	MARGINAL
AX-2026-042274	HOMO-2602-Y2822	VendorInvestigate	2026-Q3	98.71	4.72	—	Laboratory-retained	0	PASS
AX-2026-042275	HOMO-2602-Y2822	Nordanalyt	2026-Q3	99.44	5.24	92.5	Buyer-sourced	0	PASS
AX-2026-042277	HOMO-2602-Y2822	Janoshik	2026-Q3	99.57	4.79	98.8	Supplier-supplied	0	PASS
AX-2026-042278	HOMO-2602-Y2822	Kestrel	2026-Q3	99.71	4.42	—	Supplier-supplied	0	PASS
AX-2026-042279	HOMO-2602-Y2822	Janoshik	2026-Q3	99.27	4.62	90.9	Supplier-supplied	0	PASS
AX-2026-042280	HOMO-2602-Y2822	VendorInvestigate	2026-Q3	99.16	5.05	105.8	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent SLU-PP-332 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042278	Homopeptide	HOMO-2602-Y2822	Kestrel	2026-Q3	99.71	4.42	—	Supplier-supplied	0	PASS
AX-2026-042274	Homopeptide	HOMO-2602-Y2822	VendorInvestigate	2026-Q3	98.71	4.72	—	Laboratory-retained	0	PASS
AX-2026-042279	Homopeptide	HOMO-2602-Y2822	Janoshik	2026-Q3	99.27	4.62	90.9	Supplier-supplied	0	PASS
AX-2026-042280	Homopeptide	HOMO-2602-Y2822	VendorInvestigate	2026-Q3	99.16	5.05	105.8	Buyer-sourced	0	PASS
AX-2026-042273	Homopeptide	HOMO-2602-Y2822	PeptideMeter	2026-Q3	99.81	4.60	88.9	Supplier-supplied	2	MARGINAL
AX-2026-042275	Homopeptide	HOMO-2602-Y2822	Nordanalyt	2026-Q3	99.44	5.24	92.5	Buyer-sourced	0	PASS
AX-2026-042277	Homopeptide	HOMO-2602-Y2822	Janoshik	2026-Q3	99.57	4.79	98.8	Supplier-supplied	0	PASS
AX-2026-042579	GGPeps	GGPE-2511-R8569	Medutest	2026-Q2	98.58	5.09	104.0	Buyer-sourced	1	MARGINAL

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042181	Ipamorelin	HOMO-2608-A9045	Janoshik	2026-Q3	99.78	4.79	—	Supplier-supplied	1	MARGINAL
AX-2026-042172	Semaglutide	HOMO-2604-X8921	Janoshik	2026-Q3	99.64	5.16	91.9	Supplier-supplied	1	MARGINAL
AX-2026-042278	SLU-PP-332	HOMO-2602-Y2822	Kestrel	2026-Q3	99.71	4.42	—	Supplier-supplied	0	PASS
AX-2026-042180	Ipamorelin	HOMO-2608-A9045	Janoshik	2026-Q3	99.39	4.74	105.5	Supplier-supplied	1	MARGINAL
AX-2026-042184	Ipamorelin	HOMO-2608-A9045	Kestrel	2026-Q3	99.27	4.79	103.2	Supplier-supplied	1	MARGINAL
AX-2026-042274	SLU-PP-332	HOMO-2602-Y2822	VendorInvestigate	2026-Q3	98.71	4.72	—	Laboratory-retained	0	PASS
AX-2026-042183	Ipamorelin	HOMO-2608-A9045	VendorInvestigate	2026-Q3	99.38	4.97	—	Buyer-sourced	1	MARGINAL
AX-2026-042194	Retatrutide	HOMO-2605-V9833	PeptideMeter	2026-Q3	98.90	4.07	98.8	Supplier-supplied	3	MARGINAL